References
1. Brunasso AMG, Massone C. Thrombocytopenia associated with the use of antitumor necrosis factor agents for psoriasis. J Am Acad Dermatol 2009;60:781-85.
2. Pathare SK, Heycock C, Hamilton J. TNFa blocker induced thrombocytopenia. Rheumatology 2006;45:1314-15.
3. Nakahara T, Konishi S, Yasukochi Y, et al. Thrombocytopenia in a psoriatic patient sequentially treated with adalimumab, secukinumab and ustekinumab. J Dermatol 2019;46(5):e157-e158.
4. Chen M, Holland MJ, Mir MR, et al. Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor-a inhibitors. J Drugs Dermatol 2011;10:280-84.
5. Selby LA, Hess D, Shashidar H, et al. Crohn’s disease, infliximab and idiopathic thrombocytopenic purpura. Inflamm Bowel Dis 2004;10:698-700.
6. Casanova MJ, Chaparro M, Martinez S, et al. Severe adalimumab-induced thrombocytopenia in a patient with Crohn’s disease. J Crohns Colitis 2012;6:1034-1037.
7. Salar A, Bessa X, Muniz E, Montfort D, Besses C, Andreau M. Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn’s disease. Gut 2007;56:1169-1170.
8. Aster RH, Curtis BR, McFarland JG, et al. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost 2009;7:911-18.